BiotechTube
Jarvik Heart

Jarvik Heart

New York, United States· Est.
jarvikheart.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6M

Overview

Jarvik Heart is a pioneering developer of miniaturized ventricular assist devices, founded by renowned inventor Dr. Robert Jarvik. The company's core technology focuses on continuous-flow heart pumps, with its Jarvik 2000 device approved for bridge-to-transplant and lifetime use in several international markets and under investigation in the U.S. Its key innovation is the Jarvik 2015, a VAD the size of a AA battery, which is the subject of pediatric clinical trials (PumpKIN) and represents a significant advancement in treating smaller patients and enabling less invasive surgery. The company remains private, with a lean operational model centered on R&D and manufacturing in Manhattan.

CardiovascularHeart Failure

Technology Platform

Miniaturized continuous-flow axial ventricular assist devices (VADs) with integrated wireless energy transfer capability.

Funding History

2
Total raised:$6M
Grant$3.2M
Grant$2.8M

Opportunities

The pediatric VAD market is a significant unmet need with limited competition, providing a clear niche.
The trend toward device miniaturization and less invasive surgery aligns perfectly with the Jarvik 2015's design.
Successful development of wireless power transfer could address the major complication of driveline infections, creating a disruptive advantage.

Risk Factors

Lack of FDA approval for the Jarvik 2000 in the U.S.
severely limits market access.
The company faces intense competition from large, well-funded public medtech companies with established commercial networks.
As a private firm, securing sufficient capital for large-scale clinical trials and commercialization is a persistent challenge.

Competitive Landscape

Jarvik Heart competes in the LVAD market against giants like Abbott (HeartMate 3) and Medtronic (HVAD, though recently discontinued). Its primary competitive advantage is miniaturization, particularly for pediatric and small-stature patients. In pediatrics, it competes with Berlin Heart's EXCOR (a pulsatile device) and off-label use of smaller adult pumps.

More companies in Drug Delivery & Formulation →More companies in United States →